Overview

procarbazine


'procarbazine' can also refer to...

procarbazine

procarbazine

procarbazine n.

procarbazine n.

procarbazine n.

procarbazine n.

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972

High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study

Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children

DNA damage and mutagenesis induced by procarbazine in lambda lacZ transgenic mice: evidence that bone marrow mutations do not arise primarily through miscoding by O6-methylguanine.

P08.60 Primary Procarbazine, Lomustine, and Vincristine (PCV) chemotherapy (CT) in grade II/III 1p19q co-deleted gliomas: The Royal Marsden experience

AT-13R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN LOW-GRADE QLIOMA: RESULTS BY HISTOLOGIC TYPE

AT-56TREATMENT OF LARGE LOW-GRADE OLIGODENDROGLIAL TUMORS WITH UPFRONT PROCARBAZINE, LOMUSTINE, AND VINCRISTINE CHEMOTHERAPY WITH LONG FOLLOW-UP: A RETROSPECTIVE COHORT STUDY WITH GROWTH KINETICS

Alternating Combination Chemotherapy C-MOPP (Cyclophosphamide, Vincristine, Procarbazine, Prednisone) and ABVd (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) in Clinical Stage II–IV Hodgkin’s Disease: a Multicenter Phase II Study (JCOG 8905)

 

More Like This

Show all results sharing this subject:

  • Clinical Pharmacology and Therapeutics

GO

Show Summary Details

Quick Reference

(proh-kar-bă-zeen)

a drug that inhibits growth of cancer cells by preventing cell division and is administered by mouth to treat such cancers as Hodgkin's disease.

Subjects: Clinical Pharmacology and Therapeutics.


Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.